CAM
CUE icon

ClariVest Asset Management’s Cue Biopharma CUE Stock Holding History

ClariVest Asset Management’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,340
Closed -$490K – 765
2021
Q1 		$490K Buy
1,340
+437
+48% +$180K 0.02% 418
2020
Q4 		$339K Buy
903
+280
+45% +$112K 0.01% 448
2020
Q3 		$282K Buy
623
+70
+13% +$40.3K 0.01% 423
2020
Q2 		$407K Buy
+553
New +$401K 0.01% 433

Other funds holding CUE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClariVest Asset Management's CUE Position: Q2 2021 in Review

ClariVest Asset Management sold out of Cue Biopharma (CUE) in Q2 2021, closing a stake of 1,340 shares — an estimated $490K sold.

ClariVest Asset Management first reported a position in CUE in Q2 2020 and held it in 4 quarters. The position peaked at $490K in Q1 2021. 89 funds tracked by Wall St. Rank hold CUE as of Q2 2021.

  • ClariVest Asset Management reported no remaining Cue Biopharma position as of Q2 2021 after selling out during the quarter.
  • ClariVest Asset Management sold 1,340 Cue Biopharma shares in Q2 2021, an estimated $490K.
  • ClariVest Asset Management first reported a position in Cue Biopharma in Q2 2020 and held it in 4 quarters.
  • ClariVest Asset Management's Cue Biopharma position peaked at $490K in Q1 2021.
  • 89 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2021.

Based on ClariVest Asset Management's 13F filing for Q2 2021, filed 9 Aug 2021.